Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures

The study evaluated the in vitro bactericidal and molecular efficacy of ibezapolstat, vancomycin, and fidaxomicin against Clostridioides difficile and Enterococcus species in recurrent C. difficile infection. The article excerpt provides no quantitative efficacy results, clinical-trial outcomes, regulatory developments, or financial implications.